Mode
Text Size
Log in / Sign up
Phase 4 N=30 Randomized Treatment

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

Abortion, Second Trimester · PPROM · Rupture, Spontaneous · Fetal Demise · Fetal Death

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Delivery Within 12 Hours — 5; 5 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Mifepristone (Drug); Misoprostol (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Washington University School of Medicine
Primary completion
Jun 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Delivery Within 12 Hours
5; 5
SECONDARY
Delivery Within 24 Hours
12; 13
SECONDARY
Time to Delivery
950; 745
SECONDARY
Failed Induction of Labor
SECONDARY
Retained Placenta
SECONDARY
Diagnosis of Clinical Chorioamnionitis
SECONDARY
Postpartum Hemorrhage

Summary

When time allows, administration of mifepristone prior to second trimester induction of labor decreases total labor time. However, in the setting of many pregnancy complications, decreasing time from diagnosis of nonviable pregnancy to delivery is of utmost importance to decrease risk of maternal complications. Previous data has shown that total abortion time is longer in the group receiving mifepristone owing to the delay between mifepristone administration and initiation of misoprostol induction of labor. Thus, the investigators aim to investigate whether simultaneous mifepristone and misoprostol has benefits over misoprostol alone when labor induction of a nonviable second trimester cannot be delayed.

Eligibility Criteria

Inclusion Criteria

  • 18 years or older
  • 14 and 28 weeks' gestation
  • Singleton gestation
  • Nonviable fetus (i.e. fetal demise or previable gestational age/weight or lethal fetal anomaly)
  • Requires induction of labor
  • If fetal cardiac motion, abortion being performed for medical emergency per MO laws and consents completed

Exclusion Criteria

  • Contraindication to mifepristone
  • Plan for surgical evacuation of uterus
  • Contraindication to vaginal delivery
  • Plan to initiate induction with any medication or device except misoprostol
  • Declines participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05322252). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search